Journal
CELL
Volume 161, Issue 5, Pages 999-1011Publisher
CELL PRESS
DOI: 10.1016/j.cell.2015.05.011
Keywords
-
Categories
Funding
- Department of Medicine, Boston Children's Hospital
- National Institutes of Health [R01DK098496]
- American Diabetes Association Career Development grant [7-09-CD-10]
- Fidelity Biosciences Research Initiative
Ask authors/readers for more resources
Despite all modern advances in medicine, an effective drug treatment of obesity has not been found yet. Discovery of leptin two decades ago created hopes for treatment of obesity. However, development of leptin resistance has been a big obstacle, mitigating a leptin-centric treatment of obesity. Here, by using in silico drug-screening methods, we discovered that Celastrol, a pentacyclic triterpene extracted from the roots of Tripterygium Wilfordi (thunder god vine) plant, is a powerful anti-obesity agent. Celastrol suppresses food intake, blocks reduction of energy expenditure, and leads to up to 45% weight loss in hyperleptinemic diet-induced obese (DIO) mice by increasing leptin sensitivity, but it is ineffective in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mouse models. These results indicate that Celastrol is a leptin sensitizer and a promising agent for the pharmacological treatment of obesity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available